Integra Lifesciences Holdings (IART) Total Non-Current Liabilities (2009 - 2026)

Integra Lifesciences Holdings has reported Total Non-Current Liabilities for 18 years, with the latest figure at $2.3 billion in Q2 2026.

• Quarterly Total Non-Current Liabilities fell 2.12% year-over-year to $2.3 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $2.3 billion (down 2.12% YoY) and the FY2025 annual result came in at $2.4 billion, changed 0.36% from the prior year.
• Total Non-Current Liabilities eased to $2.3 billion in Q2 2026 per IART's latest filing, from $2.3 billion in the prior quarter.
• Over five years, Total Non-Current Liabilities peaked at $2.4 billion in Q2 2024 and troughed at $1.9 billion in Q1 2023.
• A 5-year average of $2.2 billion and a median of $2.3 billion in 2026 frame the typical range for Total Non-Current Liabilities.
• The sharpest annual moves came in 2022 and 2024: Total Non-Current Liabilities decreased 4.66% in 2022, then gained 22.89% in 2024.
• Over 5 years, Total Non-Current Liabilities stood at $2.1 billion in 2022, then declined by 2.85% to $2.0 billion in 2023, then gained by 17.64% to $2.3 billion in 2024, then increased by 0.36% to $2.4 billion in 2025, then declined by 1.21% to $2.3 billion in 2026.
• According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $2.3 billion, $2.3 billion, and $2.4 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.